Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

Cantor Fitzgerald adjusted its outlook on Amgen shares (NASDAQ:AMGN), reducing the price target from the previous $405.00 to $340.00. Despite the lowered price target, the firm maintained its ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.

KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Global markets have recently experienced a mix of volatility and growth, with U.S. stocks facing challenges from competitive pressures in the AI sector and political uncertainties surrounding tariffs, ...